NextCell Pharma's clinical trial on the TV3 Diabetes gala

NextCell Pharma AB ("NextCell") today announces that the application for clinical trial of COVID-19 patients with the drug candidate ProTrans has been approved by both the Ethics Committy and the Swedish Medical Product Agency. The study will be conducted at the University Hospital in Örebro in collaboration with the Department of Clinical Trials and Karolinska Trial Alliance. ProTrans is developed as an immunomodulatory stem cell therapy presently evaluated in clinical trials treating patients with type-1 diabetes. However, the mechanism of immunomodulation is expected to be applicable in

NextCell Pharma AB (“NextCell”) will today at 15:00 present at Investerarjakten. Viewers have the possibility to ask questions directly to CEO Mathias Svahn. The event is broadcast live on Studio Direct's youtube channel, the facebook group Aktier and on Investerarbrevet.se between 13:00-17:00. In September, NextCell published positive data for its Phase II study, ProTrans-2. The patients with type 1 diabetes treated with a dose of the stem cell drug ProTrans had maintained a statistically significantly higher insulin production after 12 months compared with the patients treated with placebo

NextCell Pharma AB ("NextCell") announced earlier this week that the clinical diabetes trial ProTrans-2 had met the primary endpoints. On the occation of that, the principal investigator Professor Per-Ola Carlsson together with NextCell will hold a webcast presentation today, Thursday 10 September at 16.00. The result from the clinical trial ProTrans-2 said that patients treated with a single dose ProTrans show a statistically significant improved preservation of insulin production over 12 months, compared to patients treated with placebo (p-value < 0.05). Today, on Thursday the 10th of

NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved preservation of insulin production over 12 months, compared to patients treated with placebo (p-value < 0.05). A total of 15 patients were included in the ProTrans-2 trial. They were randomized to receive either ProTrans (n=10), NextCell’s proprietary stem cell therapy, or placebo (n=5). Treatment was blinded, ensuring that neither patients or their physicians knew whether they had received active

NextCell Pharma AB (“NextCell” or the “Company”) announces today that the Company together with 3 partner organizations have been awarded a €1.6M Eurostars grant of which NextCell’s share is €470,000. The aim of the project entitled Bioscale, is to optimise automated bioreactors to manufacture the drug candidate ProTrans. The SCINUS expansion system presents cost-efficient cell culturing, designed for standardised cell therapy production, leading to improved quality consistency and reduced cost. · NextCell has been granted €470,000 of a Eurostar grant totalling €1.6M. The total budget of the

NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - May 31, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report Nine months (2019-09-01 until 2020-05-31) · Operating income amounted to SEK 3 191 314 (1 273 201). · Operating result amounted to SEK -12 803 349 (-13 477 202). · Earnings per share* amounted to SEK -1,11 (-1,17). · Cash and bank amounted to SEK 5 612 952 (2 249 092). In addition, after the end of the period, in June 2020, the Company received an

NextCell Pharma AB (publ) (“NextCell” or “the Company”) announces that Nasdaq Stockholm AB today has approved their application for trading on Nasdaq Stockholm First North. The last day for trading on Spotlight is Tuesday, July 21, 2020 and the first day for trading on Nasdaq First North is Wednesday, July 22, 2020. The shares in NextCell will be traded with unchanged ticker (NXTCL) and ISIN code (SE0009723125) and shareholders in NextCell need not take any action in connection with the list change. "The list change is a natural step in our development and is expected to attract a broader

The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders (the “Rights Issue”). The demand was high and the Rights Issue was oversubscribed. Thus, no guarantees have been utilized. Through the Rights Issue, the Company receives approximately SEK 25.1 million before transaction costs. · 4,111,192 shares were subscribed using subscription rights · In addition, applications for subscription without using subscription rights corresponding to 11,750,102 shares